Expert Discussion: SABCS 2021

[摘要] Kolberg-Liedtke: My personal highlight was the presentation of Gianpaolo Bianchini, who presented results of histranslational analysis of the NeoTRI-PaPDL1 study(NCT02620280), which aimed to generate predictive information regarding response to neoadjuvant atezolizumab therapy using imaging mass cytometry (IMC). IMC allows the study of protein expression at the single-cell leveland the location of the cells within the tumor microenvironment (TME). One must acknowledge that clinical useof this technology is yet limited, and interpretation has tobe done with caution; however, results demonstrate feasibility of this technology in the context of a clinical trial.Personally, I am particularly delighted to see those resultsgiven that translational analyses of our own clinical atezolizumab trial neoMono will also use IMC technology fortherapy response prediction. neoMono is an active openrandomized phase 2 study that will recruit up to 458 (maleor female) patients with early, therapy-naïve, triple-negative breast cancer or breast cancer with a hormone receptorpositivity of less than 10% with the goal to analyze the association between addition of a monotherapy window withatezolizumab prior to a combination of chemotherapy (anthracycline, taxane, and platinum) and atezolizumab withpathologic complete remission as primary study endpoint(defined as lack of invasive tumor cells and lymph node).Throughout the trial, longitudinal parallel liquid and tissuebiopsies will provide a basis for identification/validation ofpredictive biomarkers.

[学科分类] 泌尿医学